𝕏
Latest

Author

Clara Ashworth

Deals and business correspondent

Clara Ashworth covers biopharma mergers, acquisitions, licensing deals and corporate strategy for PharmaWire, from big-pharma takeovers to early-stage China out-licensing.

Latest from Clara Ashworth

Deals

AbbVie deepens immunology push with $10.9bn Apogee swoop

AbbVie (ABBV) has agreed to buy Apogee Therapeutics (APGE) for $10.9bn, its largest acquisition in more than five years, as the pharmaceutical group looks to strengthen its pipeline of treatments for inflammatory diseases such as atopic…